JPM kickoff: Gilead's deal ideal, Novartis' image-polishing, Teva's shutdown tally and one CEO's word on another

It's January, which means the annual J.P. Morgan Healthcare Conference in San Francisco is back on, and drugmakers of all shapes and sizes are doing their best to woo investors. What we're hearing so far? Lots of deal PRs, sales projections and cost updates, plus some skinny on how and where JPM deal talks get done—and what has to move out of the way first.